ID | 115331 |
タイトル別表記 | 甲状腺未分化癌同所移植SCIDマウスモデルへのパクリタキセルとレンバチニブの有効性に対する小動物用FDG-PET/CTを用いた非侵襲的モニタリング
MONITORING ANAPLASTIC THYROID CANCER MODELS BY PET/CT
|
著者 | |
キーワード | anaplastic thyroid carcinoma
orthotopic model
18F-FDG PET/CT
paclitaxel
lenvatinib
|
資料タイプ |
学位論文
|
抄録 | Anaplastic thyroid carcinoma (ATC) is a rare type of thyroid carcinoma with a poor prognosis. Thus, suitable preclinical tumor models are required for the development of new ATC therapies. In the present study, orthotopic tumor xenograft models were established using ATC cell lines and SCID mice, and tumor invasion and the effects of anticancer drugs were evaluated using positron emission tomography/computed tomography (PET/CT) to repeatedly and non-invasively monitor these models. Three ATC cell lines (8305c, 8505c, and ACT-1) were used. Their sensitivities to two anticancer drugs (paclitaxel and lenvatinib) were investigated. The 8505c cell line was orthotopically implanted into SCID mice, which were then divided into three groups: no chemotherapy, paclitaxel (5 mg/kg, administered intraperitoneally, every week), and lenvatinib (5 mg/kg, oral route, every day) groups. PET/CT was performed and tumor growth and the effects of anticancer drugs based on tumor volume and fludeoxyglucose (FDG) uptake were evaluated. 8505c cells exhibited the highest sensitivity to the anticancer drugs. In mice implanted with 8505c cells, continuous increases in FDG uptake associated with tumor growth were detected on PET/CT in the group that received no chemotherapy. The tumor volume and FDG uptake increased by 91.5- and 2.4-fold, respectively, within 2 weeks. The increase observed in tumor volume was 26.9- and 12.2-fold in the paclitaxel and lenvatinib groups, respectively, within 2 weeks. Furthermore, the increase in FDG uptake was 1.8-fold and 1.6-fold in the paclitaxel and lenvatinib groups, respectively, within 2 weeks. In our orthotopic SCID mouse model, tumor growth and the effects of anticancer drugs were repeatedly and non-invasively monitored using PET/CT. The present method is useful for the development of new ATC treatments.
|
掲載誌名 |
Oncology Reports
|
ISSN | 1021335X
17912431
|
cat書誌ID | AA11016405
|
出版者 | Spandidos Publications
|
巻 | 44
|
号 | 4
|
開始ページ | 1709
|
終了ページ | 1716
|
発行日 | 2020-08-07
|
備考 | 内容要旨・審査要旨・論文本文の公開
本論文は,著者Mariko Aoyamaの学位論文として提出され,学位審査・授与の対象となっている。 |
EDB ID | |
出版社版DOI | |
出版社版URL | |
フルテキストファイル | |
言語 |
eng
|
著者版フラグ |
博士論文全文を含む
|
文科省報告番号 | 甲第3461号
|
学位記番号 | 甲医第1468号
|
学位授与年月日 | 2020-09-24
|
学位名 |
博士(医学)
|
学位授与機関 |
徳島大学
|
部局 |
医学系
放射線総合センター
病院
|